Early to Candidate (E2C)
Team led by Françoise Bono, Director of Toulouse Expertise Platform, Early to Candidate Unit, Sanofi, and co-head of the project steering committee alongside Prof. Gilles Favre, Scientific Director of the Institut Claudius Regaud UMR 1037 Inserm / Université Toulouse III - Paul Sabatier / CNRS.
Early to Candidate (E2C) for the development of an active antibody on the microenvironment of the tumor cell
As part of its partnership with Aviesan, Sanofi and Institut Claudius Regaud have signed in March 2012 and for 3 years, a collaboration of translational research in the field of oncology. The goal for this team of twenty researchers: to advance knowledge on the tumor microenvironment and discover new therapeutic targets and innovative treatments tailored to patients.
How? Targeting the tumor microenvironment and the mechanisms involved in cancer:
- modulating the immune response, macrophages plasticity and mesenchymal cells,
- integrity of the extracellular matrix.
This collaboration agreement anticipates the dynamics of science campus a few months before the opening of the Cancer University Institute, future healthcare and research center.
« This collaborative research presents a double originality as it benefits from both a shared steering project and shared of resources and expertise among researchers and physicians.Gathering in one place a bank of tumors and tissues as well as clinicians and open research exchanges can only strengthen innovation.»
Françoise Bono, Director of Toulouse Expertise Platform, Early to Candidate Unit, Sanofi.